



Disclosures

- Consultant and Advisory Board Member
 - Terumo Aortic

Recurrent Thoracoabdominal Aortic Aneurysms

- TAAAs account for only 10% of all aortic aneurysms
- Literature reports of late failures are limited
- Redo open surgery carries worse morbidity and mortality than the index procedure
- Few centers have the technical expertise to safely undertake
- Endovascular therapies may improve outcomes

Outcomes and Performance Redo-OSR

Redo Thoracoabdominal Aortic Aneurysm
Repair: A Single-Center Experience 25 Years
Rana O. Afifi, MD,* Harleen K. Sandhu, MD, MPH,* Amy E. Trott, PhD, Tom C. Nguyen, MD, Charles C. Miller, PhD, Anthony L. Estrera, MD, and Hazim J. Safi, MD

- From 1991 to 2014 all 1900 DTAA/TAAA's were reviewed
- 266 (14%) required redo surgery
- Redo's were associated with younger age (62.5+/-16.4 years vs. 64.6+/-13.4 years, p < 0.02)
- Reasons for redo:
 - Extension of disease (86.8%)
 - Intercostal patch expansion(6.8%)
 - Visceral patch expansion(10.9%)
 - Infection(4.5%)
 - Anastomotic PSA(8.3)
 - Previous endovascular aortic repair complications(6.4%)

(Ann Thorac Surg 2017;103:1421-8)

Outcomes and Performance Redo-OSR

Redo Thoracoabdominal Aortic Aneurysm
Repair: A Single-Center Experience Over 25 Years
Rana O. Afifi, MD,* Harleen K. Sandhu, MD, MPH,* Amy E. Trott, PhD, Tom C. Nguyen, MD, Charles C. Miller, PhD, Anthony L. Estrera, MD, and Hazim J. Safi, MD

- From 1991 to 2014 all 1900 DTAA/TAAA's were reviewed
- Redo repairs were conducted in a similar manner to the original procedure
- Treacherous adhesions often encountered
- In HCTD, for visceral patch expansion, converted to branch graft repair
- Early mortality was 22.9%
- Long term survival between redo and non-redo
 - 5 yr 46.6% vs. 58.1%
 - 10 yr 30% vs. 43.6%
 - 15 yr 21.8% vs. 36.8%


(Ann Thorac Surg 2017;103:1421-8)

Case 1 Clinical History

- 87 yo man with continued paravisceral expansion of previous open Extent III TAAA
- 2012- Open Extent III TAAA repair w/patch of viscerals, left renal reimplantation
- 2018 - Proximal extension of disease- Tx with TEVAR x 2
- 2020- Development of Type 1B between TEVAR and Previous open graft- Tx with Coil Embolization -> Thoracic aorta expanded to 7.0cm
- 2022- Referred to for eval

Extraordinarily healthy:

- EF- 65%
- Cr- 1.1
- PFT's- normal






Case Considerations

- **Surgical Options**
 - Redo Open TAAA Repair
 - Visceral Debranching via transperitoneal approach with distal stent graft
- **PMEG/BEVAR/FEVAR**
 - Technical considerations
 - Aneurysm diameter and distance to visceral ostia
 - Visceral architecture and trajectory
 - Inner-branch vs. outer-branch options
 - Preservation of intact intercostal arteries

Terumo RELAY PRO TEVAR

4 Vessel PMEG with RELAY PRO

- **A- Spiral Support Bar**
 - Can cause excessive torque, removal often required
- **B- Extended spacing between struts**
 - Highly customizable
- **C- Low Profile**
 - 2-4 Fr size smaller than competitive grafts
 - Two stage inner sheath deployment
 - Advantageous for sequential deployment and cannulation






Case 2 Clinical History

- 78 yo man with continued super celiac expansion after previous Extent IV TAAA
 - 2018- Open Extent IV TAAA repair w/ Branched Cosell Graft
 - 2020- Dx with small cell lung cancer started on chemo/radiation
 - 2021- Expansion of super celiac aorta to 5.1
 - 2022- Continued expansion to 6.0 cm and now in remission
 - 2023- Cleared by oncology for repair

Since Repair:





- Developed large abdominal wall ventration
- Right renal graft occlusion
- Hostile iliac access
- Proximal TEVAR placed as first stage





Case Considerations

- Surgical Options
 - Redo Open TAAA Repair would be hostile with the loss of domain
- PMEG/BEVAR/FEVAR
 - Technical considerations
 - Staging likely necessary to convert to Extent II/III repair
 - Visceral architecture and trajectory/main posterior left renal
 - Preservation of intercostal arteries for spinal perfusion
 - 2 Stage-> TEVAR-> 4 Vessel PMEG with plan for occlusion of perfusion fen 6-8 weeks later.



Conclusions

- Staging is critical to reduce spinal ischemia rates
- FEVAR is a viable solution but BEVAR maybe more appropriate in certain anatomies
- FEVAR can remain a total transfemoral approach for most
- Its important to ensure good life expectancy
- Early results of F/BEVAR for failed open TAAA repair are promising